252 related articles for article (PubMed ID: 24257371)
1. Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.
Oliveira-Ferrer L; Wellbrock J; Bartsch U; Penas EM; Hauschild J; Klokow M; Bokemeyer C; Fiedler W; Schuch G
Mol Cancer; 2013 Nov; 12(1):144. PubMed ID: 24257371
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.
Yao B; He QM; Tian L; Xiao F; Jiang Y; Zhang R; Li G; Zhang L; Hou JM; Wang L; Cheng XC; Wen YJ; Kan B; Li J; Zhao X; Hu B; Zhou Q; Zhang L; Wei YQ
Hum Gene Ther; 2005 Sep; 16(9):1075-86. PubMed ID: 16149906
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
4. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
5. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO
Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879
[TBL] [Abstract][Full Text] [Related]
6. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Chakrabarti M; Ray SK
Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
[TBL] [Abstract][Full Text] [Related]
8. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
9. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
10. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
11. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
12. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins.
Sudhakar A; Sugimoto H; Yang C; Lively J; Zeisberg M; Kalluri R
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4766-71. PubMed ID: 12682293
[TBL] [Abstract][Full Text] [Related]
13. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.
Szentirmai O; Baker CH; Bullain SS; Lin N; Takahashi M; Folkman J; Mulligan RC; Carter BS
J Neurosurg; 2008 May; 108(5):979-88. PubMed ID: 18447716
[TBL] [Abstract][Full Text] [Related]
14. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models.
Park JH; Kim MJ; Kim WJ; Kwon KD; Ha KT; Choi BT; Lee SY; Shin HK
Cancer Lett; 2020 May; 478():71-81. PubMed ID: 32173479
[TBL] [Abstract][Full Text] [Related]
15. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
16. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.
Goto T; Ishikawa H; Matsumoto K; Nishimura D; Kusaba M; Taura N; Shibata H; Miyaaki H; Ichikawa T; Hamasaki K; Nakao K; Maeshima Y; Eguchi K
Int J Oncol; 2008 Jul; 33(1):33-40. PubMed ID: 18575748
[TBL] [Abstract][Full Text] [Related]
17. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
18. NEO212, a conjugate of temozolomide and perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma.
Marín-Ramos NI; Jhaveri N; Thein TZ; Fayngor RA; Chen TC; Hofman FM
Cancer Lett; 2019 Feb; 442():170-180. PubMed ID: 30392789
[TBL] [Abstract][Full Text] [Related]
19. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas.
Li Y; Fu SY; Wang LH; Wang FY; Wang NN; Cao Q; Wang YT; Yang JY; Wu CF
Cancer Lett; 2015 Dec; 369(1):86-96. PubMed ID: 26254539
[TBL] [Abstract][Full Text] [Related]
20. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
